A study of 10,775 high-risk adult patients during the COVID-19 delta variant surge in late 2021 finds that treatment with one of three anti-spike neutralizing monoclonal antibodies for mild to moderate symptoms led to low rates of severe disease, hospitalization, ICU admission and mortality, according to Mayo Clinic researchers.
Among patients treated at Mayo Clinic in Minnesota and Wisconsin from Aug. 1 to Dec. 1, 2021, who received bamlanivimab/etesevimab, casirivimab/imdevimab or sotrovimab, 287 patients, or 2.7%, developed severe disease that led to hospitalization, oxygen supplementation or death within 30 days of treatment. The rates of severe disease were 1.2% for patients treated with bamlanivimab/etesevimab, 1.6% for patients with sotrovimab, and 2.9% for casirivimab-imdevimab.
The slightly higher rate of severe outcomes among patients treated with casirivimab/imdevimab may be related to a significantly lower COVID-19 vaccination rate in that group of patients, according to Raymund Razonable, MD, a Mayo Clinic infectious diseases specialist and first author of the study, published in Mayo Clinic Proceedings. Data show that unvaccinated patients are at higher risk of serious disease. ICU admission was comparable among patients treated with the three anti-spike monoclonal antibody products.
"Anti-spike neutralizing monoclonal antibodies are effective in reducing the risk of hospitalization and severe disease due to COVID-19," Razonable says. "The improved clinical outcomes are shown for all three monoclonal antibodies that were used during the delta surge. That surge has passed, and we're now dealing with omicron and its variants. But the lessons learned from the delta experience are still true: Diagnose early, treat early with monoclonal antibodies, and the risk of severe disease will be reduced."
The delta COVID-19 variant is nearly twice as contagious as earlier variants and may cause more severe illness. The greatest risk of transmission is among people who are unvaccinated. People who are fully vaccinated still can be infected and spread the virus to others, though it appears that vaccinated people spread COVID-19 for a shorter period than unvaccinated people do.
Patients in the Mayo Clinic study were not confirmed as having the delta variant, but Razonable says the assumption is that patients were infected with that variant.
"We do not routinely perform genetic testing for all patients but based on tracking by the Centers for Disease Control and Prevention, almost all cases were delta during the study period," he says.
Only patients treated at Mayo Clinic locations in Minnesota and Wisconsin were included in the study. This allowed for more accurate comparison of the three antibody products, given similar circulating variants in those communities.
The specific monoclonal antibody administered to an eligible patient was based only on the product that was available at the infusion facility on the date of treatment. No clinical criteria favored one product over another, and all patients received education about the monoclonal antibody product, the potential benefits and adverse effects, and the investigational status of the drug. The monoclonal antibody product was administered within 10 days of symptom onset.
During the 30 days after monoclonal antibody infusion, most patients who progressed to severe disease were not fully vaccinated. Of the 104 patients who required ICU level of care, 69% were not fully vaccinated. Twenty-five patients died within 30 days after infusion, and all were not fully vaccinated.
The authors note that most patients in the study were non-Hispanic white people who sought care at a large academic medical center. The results may not be generalizable to underrepresented populations.
"Monoclonal antibodies work," says Razonable. "They work best when given early. The most benefit can be gained by people at highest risk of disease progression. The key takeaway for health care professionals and patients is: Test early so we can treat early."